In an Editor’s Special Episode of The HemOnc Pulse, William G. Wierda, MD, PhD, explores the evolving treatment protocols for CLL.
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Immunotherapy is transforming lymphoma treatment, reducing chemo reliance, and improving long-term outcomes.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Podcasts
Dr. Hira Mian reviews selinexor, talquetamab, and emerging trispecifics shaping the future of multiple myeloma care.
In a podcast, experts explore chemo-free ALL therapies, CAR T breakthroughs, and the future of T-cell–targeted treatments.
Exploring treatment sequencing, prior therapy impact, and targeted approaches in lower-risk myelodysplastic syndromes.
A group of experts led by Naval Daver, MD discuss mutation loss, MRD dynamics, and transplant timing in evolving AML care.
Experts spotlight promising new CAR T-cell and bispecific therapies shaping the future of myeloma treatment.
Explore expert insights on bispecifics, CAR T-cell therapy, and emerging regimens for B-cell lymphomas.
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Editorial Board
Mehdi Hamadani, MDProfessor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin
Krina Patel, MD, MScAssociate Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center
Uma Borate, MBBSAssociate Professor in the Division of Hematology at The Ohio State University
Rahul Banerjee, MD, FACPAssistant Professor, Division of Hematology and Oncology, University of Washington
Hira Mian, MD, MSc, FRCPCAssociate Professor in the Department of Oncology at McMaster University
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
ManniMD1
ManniMD1Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
BloodJournal
BloodJournalStudy finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
NatureRevClinOncol
NatureRevClinOncolYesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
The Lancet Haematology
The Lancet Haematology NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.